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Abstract
Purpose To evaluate fluorine-18 fluorocholine (FCH)
PET/CT for the detection of recurrent prostate cancer in
relation to prostate-specific antigen (PSA) level.
Methods FCH PET/CT was performed in 50 patients with
rising PSA levels at follow-up of primary treatment of
prostate cancer (radical prostatectomy in 28, radiation
therapy in 13, and brachytherapy in 9). PET detection rates
were determined at various PSA thresholds and examined
by receiver operating characteristic analysis.
Results Findings consistent with recurrent prostate cancer
were noted on FCH PET/CT in 31/50 (62 %) patients, with
positive findings in 17/18 (94 %), and 11/13 (85 %), 2/7
(29 %), and 1/12 (8 %) patients with PSA [4, [2–4,
[0.5–2, and B0.5 ng/mL, respectively. These findings
were indicative of local/regional recurrence in 23 cases and
systemic recurrence in 8 cases, with only a single route of
recurrence (i.e., either hematogenous, lymphatic, or intra-
prostatic) in 84 % of PET scans with positive findings.
Abnormal tumor activity was detected in 88 % of patients
with a PSA level of 1.1 ng/mL or higher, and in only 6 %
of patients with a PSA level below this threshold value.
Conclusion FCH PET/CT may serve to identify the route
of tumor progression in patients with recurrent prostate
cancer; however, the likelihood of tumor detection may be
related to the PSA level at the time of imaging.
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Introduction
A rising serum prostate-specific antigen (PSA) level is
often the first indicator of recurrent disease in patients with
prostate cancer treated with radiation therapy (RT) or
radical prostatectomy (RP). At 5 years following such
primary treatments, rising PSA levels can be detected in
approximately 15–20 % of low-risk patients, and approxi-
mately 50 % of high-risk (i.e., Gleason score 8–10, PSA
[20 ng/mL, stage T3) patients [1, 2]. Localizing recurrent
tumors in these patients has proven to be a significant
challenge when using conventional diagnostic imaging,
particularly when the PSA level has not yet risen sub-
stantially [3–5]. While recurrence patterns in prostate
cancer are known to vary by treatment [6, 7], awareness of
these patterns is not sufficient to support the customization
of salvage therapy for recurrent prostate cancer. Patient-
individualized treatment approaches for recurrent prostate
cancer could be enhanced if tumor spread along local,
lymphatic, and hematogenous routes are correctly identi-
fied shortly after a rise in PSA is detected.
PET imaging using tracer analogs of choline has shown
significant promise for detecting prostate cancer [8–13].
The rationale for using choline derivatives as oncologic
PET tracers is based on the observation that choline
transport and phosphorylation are upregulated in most
cancers, including prostate cancer [14–17]. While there are
some data on the performance of choline-based PET
imaging for whole-body staging of prostate cancer, some
uncertainty remains as to its diagnostic sensitivity in
patients with low levels of PSA following RP, external
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beam RT, and interstitial brachytherapy. The purpose of
this study is to evaluate the detection rate of FCH PET/CT
in patients with rising PSA levels following primary
treatment of prostate cancer, paying particular attention to
the routes of tumor progression that can be identified as




Fifty sequential patients with a history of clinically local-
ized prostate cancer who were noted to have an elevated
PSA level[0.2 ng/mL on at least two serial measurements
after completion of RP, RT, or interstitial brachytherapy
were recruited to undergo FCH PET/CT imaging in this
institutional review board-approved clinical research study.
All patients gave written informed consent before their
participation. Hormone-naı¨ve patients as well as patients
who received luteinizing hormone-releasing hormone
(LHRH) agonist therapy for at least 3 months prior to the
detection of an elevated PSA, including those treated with
an LHRH agonist in conjunction with primary treatment,
were eligible for this study. However, patients in whom
LHRH agonist therapy was started recently, namely within
3 months, or following the detection of an elevated PSA
level were excluded from the study.
Radiopharmaceutical synthesis and PET imaging
FCH synthesis was performed by fluorination of ditosylme-
thane with fluorine-18 followed by alkylation of the fluor-
otosylmethane intermediate with dimethylethanolamine
using a chemical process control unit (CTI/Siemens CPCU,
CTI/Siemens, Knoxville, TN) [18]. All synthesis products
passed standard assays for radiochemical purity, radionuclidic
identity, chemical purity, and pyrogenicity prior to injection.
Radiochemical purity was[99 %.
PET/CT imaging
Patients refrained from eating or drinking for at least 3 h
prior to PET/CT. Scans were performed using a Philips
Gemini TF-64 PET/CT scanner (Philips Healthcare,
Andover, MA). A CT transmission scan was first per-
formed in the supine position from the pelvis to the skull.
The 64-channel helical CT scanning parameters were:
120 kV, 50 mA/slice, rotation time 0.75 s, slice thickness/
interval 5.0 mm. No intravenous contrast was used for CT.
At approximately 12–15 min after intravenous injection of
2.6 MBq/kg (0.07 mCi/kg) of FCH, emission scans were
acquired from mid-thigh to skull over 9–11 bed positions at
2 min per bed position. Image reconstruction employed a
list-mode version of a maximum likelihood expectation
maximization algorithm. CT data were used for attenuation
correction.
Image interpretation and analysis
PET/CT images were visually assessed by two readers (SK,
a nuclear medicine physician; MC, a radiologist). Both
have extensive experience in the interpretation of whole-
body FCH PET/CT. All PET/CT images were interpreted
initially without access to the clinical data. The scans were
classified as positive if a focal area of increased FCH
uptake was visually identified in the bone, lymph node,
visceral organ, or prostate gland (e.g., Fig. 1). The finding
of increased uptake in inguinal, hilar or axillary nodes was
Fig. 1 FCH PET/CT of recurrent prostate cancer after interstitial
brachytherapy. a Axial PET image through the pelvis demonstrates
focal increased activity in the prostatic region (arrow). b The
corresponding CT image reveals the presence of brachytherapy
implants in the prostate without other significant structural
abnormality. c On PET/CT, images through the prostatic region
localize to the area of increased FCH uptake to the left seminal
vesicle and basal prostate (arrow). A subsequent biopsy of the left
prostatic base confirms the presence of recurrent prostate cancer
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an exception to this criterion, given that increased FCH
uptake in benign reactive lymph nodes is known to occur
[11]. The maximum standardized uptake value (SUVmax),
defined as the highest ratio of measured activity to
injected activity normalized to body weight, was recorded
for each corresponding lesion by region of interest
analysis.
Findings on FCH PET/CT were compared to clinical
pathology and imaging data available at the time of imag-
ing, as well as data obtained prospectively that included
subsequent biopsy results, imaging studies and serial PSA
measurements. In addition to using histology as the standard
of reference, non-histologic criteria for recurrent metastatic
prostate cancer were employed and based on radiographic
findings of either (1) a marrow-based lesion showing
abnormal signal intensity or enhancement on MRI, (2)
evidence of bone destruction or invasion by tumor on CT
scan, or (3) tumor enlargement on serial CT or MRI coin-
ciding with a rising PSA. All patients also received a bone
scintigraphic scan with Tc-99m-oxidronate (Technescan
HDP, Mallinckrodt) within 2 months of enrollment. These
scans were classified as unremarkable, non-specific, or
consistent with metastatic disease based on their clinical
interpretation.
Statistical analysis
Contingency tables were tested for significance using the
Fisher exact test. Correlations were assessed by the Pearson
product moment coefficient. Group differences were
assessed by ANOVA. Receiver operating characteristic
analysis was used to assess optimal cutoff points for PSA to
predict positive findings on PET/CT. All tests were two
tailed. Statistical analyses were performed using JMP 9 and
SAS v 9.2 (SAS Institute, Inc., Cary, NC).
Results
Clinical data
Patient clinical data are summarized in Table 1. The
median time interval between primary therapy and PSA
recurrence was 48 months (range 3–219 months). The
median PSA level at the time of initial PET/CT scanning
was 3.2 ng/dL (mean 5.2, range 0.2–18.1). PSA levels did
not differ significantly between RP, RT, and brachyther-
apy-treated patients (mean ± SD; 4.3 ± 1.0, 4.5 ± 1.4,
and 5.6 ± 1.7, respectively, p = 0.68). PSA values did not
differ significantly between LHRH agonist-treated and
-untreated patients (7.1 and 4.2 ng/mL, respectively,
p = 0.33).
FCH PET/CT findings
FCH PET/CT demonstrated positive findings in 31/50
(62 %) of patients. There was inter-observer agreement in
the classification of a positive FCH PET/CT scan in all
cases. Biopsy results were available to confirm the status of
abnormal FCH PET/CT findings in 10/31 of the positive
PET cases. Radiographic follow-up with serial bone scin-
tigraphy, CT, and MRI for up to 6 months was successful
in classifying all remaining FCH PET/CT results. PET/CT
findings were consistent with local or regional recurrence
in 23 cases and systemic recurrence in 8 cases. The
abnormal findings on FCH PET/CT involved only a single
organ system (i.e., the skeletal system, lymph nodes, or
prostate) in 26/31 (84 %) of patients with positive scans.
Positive findings occurred in 17/18 (94 %), 11/13 (85 %),
2/7 (29 %), and 1/12 (8 %) of patients with PSA[4,[2–4,
[0.5–2, and B0.5 ng/mL, respectively (Fisher exact
p = 2.79E-07). The proportion of positive FCH PET/CT
findings in patients receiving LHRH agonist therapy was
not significantly different than in untreated patients (10/15
(81 %) and 22/35 (63 %), respectively, p = 0.757).
The optimal PSA threshold for discriminating FCH
PET/CT scans with positive findings was determined by
receiver operating characteristic analysis to be 1.1 ng/mL.
Based on this threshold, 88 % (30/34) of the patients with a
PSA C1.1 ng/mL had positive PET/CT results (Fig. 2).
The only FCH PET/CT that was positive below this
threshold corresponded to a patient with PSA level of
Table 1 Patient clinical data
n
Total patients 50
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0.3 ng/mL in whom a single retroperitoneal lymph node
was detected on the basis of increased FCH uptake on PET/
CT (Fig. 3). Thus, diagnostic sensitivity of FCH PET/CT
on a per patient basis in this study was 88 % in patients
with a PSA level of 1.1 ng/mL or higher.
Two patients had bone scintigraphic findings consistent
with metastatic disease. Four additional patients had bone
scintigraphic studies classified as unremarkable (n = 2) or
non-specific (n = 2), but were noted to have areas of
abnormal skeletal FCH uptake on corresponding PET/CT.
Radiographic follow-up in all cases, along with biopsy in
one of the cases associated with a non-specific bone scan
finding (Fig. 4), confirmed the FCH PET/CT findings to be
metastatic disease. Specific patterns of abnormal findings
on FCH PET/CT for each treatment category are summa-
rized in Table 2.
Discussion
Clinical outcomes for patients with recurrent prostate
cancer could improve further if salvage treatments were
individualized based on accurate delineation of cancer
recurrence. Unfortunately, the localization of recurrent
prostate cancer remains a significant diagnostic challenge,
particularly at low PSA levels. In this study, it proved
possible to identify local, lymphatic, and hematogenous
routes of metastatic disease progression on the basis of
whole-body FCH PET/CT with tumor detection rates
directly correlated to PSA levels at the time of imaging.
Such a relationship between PSA level and the detection
of prostate cancer by PET was first reported in studies
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Fig. 2 Receiver operating characteristic analysis of PSA values as
predictor of positive FCH PET/CT results. The area under the curve
was 0.93. The optimal PSA cutoff was determined to be 1.1 ng/mL
Fig. 3 Isolated retroperitoneal lymph node detected at a PSA of
0.3 ng/mL. a An 11-mm diameter retroperitoneal lymph node
(arrowhead) with maximum SUV of 2.7 was the only abnormality
found on FCH PET/CT in this patient with PSA of 0.3 ng/mL. This
finding corresponds to the lowest PSA value associated with a
positive FCH PET/CT result in this study. Note that the left ureter
(thin arrow) is laterally adjacent to this lymph node. Because FCH is
excreted into the urine, careful anatomical correspondence with CT
images is necessary to avoid a misinterpretation due to urinary
artifacts. Gentle fluid restriction was also used in this patient to reduce
the amount of ureteral activity at the time of PET scanning. b At
follow-up, this lymph node was found to be enlarged, measuring
13 mm on diagnostic CT performed with oral and intravenous
contrast after the PSA level had risen to 1.0 ng/mL in 1 month.
Additional lymph nodes measuring up to 6 mm (not shown) were also
found along the left retroperitoneum at follow-up
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11C-choline PET correctly detected tumor recurrence in
78 % of patients after external beam RT and 38 % of
patients after RP, although there were no positive scan
results at a PSA level below 5 ng/mL [12]. Another study
which focused on post-RP patients with biopsy-confirmed
tumor recurrences reported a more favorable diagnostic
sensitivity of 89 % and positive predictive value of 72 %
for 11C-choline PET/CT detection of recurrent prostate
cancer at PSA \2.5 ng/mL [19]. A direct relationship
between positive findings on 11C-choline PET/CT and PSA
level in patients with recurrent prostate cancer was sug-
gested in one study, with detection rates of 36, 43, and
62 % noted at PSA values of\1, 1 to\2, and 2 to\3 ng/
mL, respectively [13]. Higher detection rates with
11C-choline PET/CT have also been associated with higher
PSA velocities or shorter doubling times [20].
The potential relationship between PSA level and tumor
detection using fluorine-18 labeled choline analogs has also
been investigated. Despite potential advantages to imaging
with a fluorine-18 labeled PET tracer, findings from two
studies also suggest that FCH PET/CT sensitivity dimin-
ishes as the PSA level approaches the 1–4 ng/mL range
[9, 21]. Another recent study of FCH PET/CT estimated
the diagnostic sensitivity in post-prostatectomy patients to
Fig. 4 Metastatic prostate cancer response to androgen deprivation.
a Bone scintigraphy shows a solitary abnormal finding in the left
ischium (white arrow). This finding was deemed equivocal in the
absence of any other scintigraphic findings suggestive of metastatic
disease. b FCH PET demonstrated a corresponding focus of increased
uptake in the same region (arrow) with a maximum SUV of 5.5. c On
PET/CT, sclerotic changes in the ischium are evident around the area
of increased PET activity. As was the case with bone scintigraphy,
there was no other evidence of metastasis on CT. d MRI directed by
the PET findings demonstrated a corresponding 1-cm diameter
marrow-based lesion in the left ischium (arrow). A CT-guided biopsy
of this lesion confirmed it to be metastatic prostate cancer. e A second
follow-up PET/CT scan following hormonal therapy shows normal-
ization of FCH uptake in the left ischium. This change in FCH uptake
coincided with a fall in the PSA level to 0.1 ng/mL. f A persistent
sclerotic area in the left ischium can be seen on CT, although the
abnormal activity on PET did resolve in concert with the PSA
response









5 (42 %) 11 (38 %) 3 (33 %)
Abnormal FCH PET/CT findings
Prostate only 2 (17 %) 0 (0 %) 5 (56 %)
Prostate and lymph
nodes
3 (25 %) 0 (0 %) 0 (0 %)
Prostate and bone
lesions
0 (0 %) 0 (0 %) 1 (11 %)
Lymph nodes only 1 (8 %) 13 (45 %) 0 (0 %)
Lymph nodes and
bone lesions
0 (0 %) 1 (3 %) 0 (0 %)
Bone lesions only 1 (8 %) 2 (7 %) 0 (0 %)
Visceral organ
metastasis
0 (0 %) 2 (7 %) 0 (0 %)
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be 20, 44, and 81.8 % at PSA levels of B1,[1 and B5, and
[5 ng/mL, respectively [22]. These previous studies are in
accord with the current study. Notably, the current study
was drawn from a predominantly Asian population and
32/50 of the patients enrolled were of Asian ancestry. In
contrast, the previous studies were conducted in Europe at
institutions where the clinical use of FCH was pioneered.
The current study therefore serves to generalize some of
the performance characteristics of FCH PET/CT to a
population of prostate cancer patients that may differ from
Western patients, particularly with regard to responsive-
ness to hormonal therapy and rates of disease progression
[23, 24].
Sub-optimal detection rates at lower PSA values could
potentially limit the value of FCH PET/CT in guiding
treatment decisions for prostate cancer salvage therapy.
This is because disease control rates for salvage treatments
such as external beam radiation for recurrent prostate
cancer following RP are also known to vary as a function
of PSA level. For example, 6-year progression-free sur-
vival for salvage radiotherapy in patients with PSA levels
of 0.5, 0.51–1.0, 1.01–1.5, and [1.5 ng/mL have been
estimated at of 48, 40, 28, and 18 %, respectively [25].
Thus, the PSA range associated with ideal detection rates
for choline-based PET/CT may fall above the critical range
of PSA values, where salvage therapy would provide the
greatest clinical benefit. However, since detection failures
with PET could be related to low tumor volume, there
should be some prognostic relevance associated with a
negative result on FCH PET/CT. Prognostic information
gleaned from FCH PET/CT could therefore potentially aid
in decisions on the timing of aggressive treatments. Further
research is needed to determine the value of FCH PET/CT
as a prognostic tool in patients with recurrent prostate
cancer.
As a potential limitation, this study employed more than
one method for confirming abnormal PET/CT findings,
since biopsy confirmation was not always feasible to pur-
sue in the clinical setting. Longitudinal follow-up and
imaging were therefore necessary when biopsy data were
unavailable for correlation with FCH PET/CT findings.
The use of several methods as the standard of reference is
not unusual for studies evaluating diagnostic imaging tests
for recurrent prostate cancer due to the limited availability
of tissue biopsy confirmations of metastatic disease in these
patients.
In this study, visual analyses served to classify PET scans
as either positive or negative for tumor recurrence, intro-
ducing potential subjectivity in PET/CT interpretations. An
alternative approach would have been to apply a semi-
quantitative threshold such as SUV as a discriminator of
malignant involvement. Although a tumor-to-background
ratio [2 correctly classified all abnormal lesions in this
study, diagnostic thresholds based on SUV have not yet
been validated for FCH PET/CT, and such criteria could
vary depending on the imaging protocol being used [26].
Fortunately, many anatomic regions predisposed to meta-
static involvement by prostate cancer, such as the bone
marrow and pelvic lymphatics, exhibit relatively low FCH
uptake under normal conditions, making these areas ame-
nable to visual inspection. Furthermore, since all patients
underwent primary treatments for prostate cancer, focal
increases in activity within the prostatic region could be
considered abnormal for the purpose of this study. A decade
of mutual experience in FCH PET and PET/CT likely
underlies the strong concordance between the two image
interpreters in this study. However, as with any PET tracer,
all readers must be aware of the normal tracer biological
distribution and normal variants in uptake for image inter-
pretations to be reproducible. Although no false-positive
results were encountered in this study, there are several
issues known to limit the diagnostic specificity of FCH
PET/CT [27]. First, is non-specific increased uptake by
benign lymph nodes, particularly those in the axillary,
mediastinal/hilar, and inguinal regions [27, 28]. Another
issue which may lead to interpretive pitfalls is the excretion
of intact radiopharmaceutical by the renal system. As illus-
trated in Fig. 3, careful study of retroperitoneal and pelvic
anatomy with anatomical CT correspondence is essential for
accurately assessing pathologic findings in prostate cancer.
Treatments for recurrent prostate cancer could benefit
from further individualization based on the mode of tumor
recurrence depicted by imaging. For example, localized RT
may be guided to lesions that may lead to pathologic
fracture or urinary obstruction, thus reducing the risk of
metastatic complications. By differentiating the sites of
tumor recurrence, imaging may also help in selecting
patients who may benefit from novel drugs that target a
specific mechanism of metastatic progression. For exam-
ple, a patient found to have bone-dominant metastatic
disease may be steered toward treatments that can specif-
ically interfere with the osteomimetic properties of prostate
cancer. Estimations of tumor burden in the later stages of
prostate cancer may also prove useful for planning pallia-
tive options. Thus, there are multiple opportunities for
integrating FCH PET/CT into the clinical management of
recurrent prostate cancer.
Conclusion
FCH PET/CT may facilitate the single-step whole-body
assessment of metastatic recurrence and tumor progression
in prostate cancer patients with rising PSA levels after
primary therapy. This technique has shown the ability to
assess disease progression along all known routes of
506 Ann Nucl Med (2012) 26:501–507
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prostate cancer recurrence (local, lymphatic and hematog-
enous), although the likelihood of tumor detection may be
related to the PSA level.
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